dactinomycin has been researched along with volasertib in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Brabetz, S; Chan, JA; Herold-Mende, C; Kool, M; Korshunov, A; Mack, N; Milde, T; Pfister, SM; Schmidt, C; Schubert, NA; Schwalm, B; Selt, F; Witt, O | 1 |
1 other study(ies) available for dactinomycin and volasertib
Article | Year |
---|---|
Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Proliferation; Child, Preschool; Dactinomycin; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms, Germ Cell and Embryonal; Neuroectodermal Tumors, Primitive; Pteridines; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |